Latest Conference Coverage

The professor of neurology at NYU Grossman School of Medicine discussed how innovative startups are using proof-of-concept studies and devices like responsive neurostimulators to improve patient outcomes. [WATCH TIME: 6 minutes]

Epileptologists Siddharth Jain, MD, MBBS, and Cemal Karakas, MD, provided commentary on a poster presentation at AES 2024 focusing on factors influencing seizure freedom in children who’ve experienced neonatal and perinatal arterial strokes.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jonathon Parker, MD, PhD. [LISTEN TIME: 23 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jonathan Parker, MD, PhD. [LISTEN TIME: 23 minutes]

Hugo Xi, head of Medical Neurology at UCB, discussed the company’s groundbreaking research, innovations in epilepsy care, and the company’s commitment to advancing treatments for rare syndromes at the 2024 AES Annual Meeting.

The director of epilepsy surgery at Allegheny Health Network discussed how clinicians can successfully pinpoint the source of epilepsy in the brain through innovative procedures like stereo electroencephalography.

The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona provided context on the potential of regenerative therapies like stem cells to restore neural function in patients with epilepsy. [WATCH TIME: 3 minutes]

Most treatment-emergent adverse events were mild or moderate, with low rates of serious TEAEs leading to discontinuation (1.7% in DS and 2.2% in LGS patients).

New data from the phase 3 SKYLINE study suggests soticlestat as a promising adjunctive therapy for seizures among children and young adults living with Dravet syndrome.

Krista L. Lanctôt, PhD, professor of psychiatry and pharmacology at the University of Toronto, talked about findings from a recent post hoc analysis presented at CTAD 2024 on nabilone for agitation in Alzheimer disease.

Factors like education level, hypertension, diabetes, and depression did not significantly predict epilepsy risk in patients with dementia.

Brad Chapman, head of U.S Epilepsy and Rare Syndromes at UCB, provided context on some of the innovative research and studies being presented at the 2024 American Epilepsy Society Annual Meeting.

In both the randomized controlled trial and open-label extension, a higher proportion of patients without VNS achieved at least 50% and 75% seizure reductions compared to those with concomitant VNS treatment.

The Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center highlighted the benefits and challenges of using stiripentol, an FDA-approved treatment for Dravet syndrome. [WATCH TIME: 4 minutes]

Fenfluramine showed a consistent safety profile in treating Lennox-Gastaut syndrome, with common adverse events such as decreased appetite, fatigue, and somnolence.

The epileptologist at UCLA Health provided perspective on a poster presented at AES 2024 that characterized a specific subgroup of patients with developmental epileptic encephalopathy and their response to certain therapies. [WATCH TIME: 3 minutes]

A recent study presented at AES 2024 revealed that plasma p-tau217 linked to memory decline and sleep disruptions in late-onset epilepsy, highlighting its potential as a biomarker.

Although the study was limited, the data warrant further research and a raised awareness of the elevated risk associated with sleep apnea comorbidities in younger patients with epilepsy.

Participants in the intervention group also reported themes of increased connectivity, creativity, and positivity.

Treatment with relutrigine resulted in a 46% placebo-adjusted reduction in motor seizures, along with a well-tolerated safety profile with adverse events that were mild to moderate.

The director of epilepsy surgery at Allegheny Health Network talked about research recently presented at AES 2024 on stereo-electroencephalography, a minimally invasive treatment for patients with epilepsy. [WATCH TIME: 7 minutes]

Treatment with bexicaserin, a highly selective 5-HT2c receptor superagonist, resulted in reduction in countable motor seizures in patients not previously exposed to the agent.

In a further date from the ongoing open-label extension of the phase 2b X-TOLE study, results demonstrated that the majority of treatment-emergent adverse events associated with azetukalner were mild or moderate.

A recent study presented at AES 2024 showed that fewer than 15% of doses of diazepam nasal spray administered to pediatric patients with epilepsy required a second dose in 24 hours.

CBD maintained a favorable safety profile, with 63% of participants experiencing adverse events such as diarrhea, vomiting, decreased appetite, and lethargy, leading to discontinuation in four patients.

Rachana K. Gandhi Mehta, MBBS, an assistant professor of neurology at Wake Forest School of Medicine, discussed a new, innovative trial assessing the therapeutic potential of self-administered subcutaneous rozanolixizumab as a treatment for myasthenia gravis.

Findings from a phase 2/3 study demonstrated the efficacy and safety of a higher dose regimen of nusinersen in treating spinal muscular atrophy in both treatment-naïve and previously treated patients.

These results highlight the age range and ambulation status for which viltolarsen is a key treatment option for DMD patients amenable to exon 53 skipping.